CareDx (CDNA) Set to Announce Earnings on Thursday

CareDx (NASDAQ:CDNA) will likely be posting its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $0.2548 per share and revenue of $121.95 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last issued its earnings results on Thursday, July 30th. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.14. The business had revenue of $131.95 million during the quarter, compared to analysts’ expectations of $114.05 million. CareDx had a net margin of 24.23% and a return on equity of 2.87%. The company’s quarterly revenue was up 52.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.16) earnings per share. On average, analysts expect CareDx to post $0.47 EPS for the current fiscal year and $0.63 EPS for the next fiscal year.

CareDx Stock Up 2.2%

Shares of NASDAQ CDNA opened at $70.74 on Thursday. The firm has a 50-day simple moving average of $56.34 and a 200-day simple moving average of $37.35. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of 407.06 and a beta of 2.38. CareDx has a 52 week low of $14.03 and a 52 week high of $72.71.

Insider Buying and Selling at CareDx

In other CareDx news, Director Christine Cournoyer sold 16,000 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total value of $751,040.00. Following the completion of the sale, the director directly owned 42,943 shares in the company, valued at $2,015,744.42. This represents a 27.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Bickerstaff, III sold 20,000 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total value of $925,600.00. Following the completion of the sale, the director directly owned 134,061 shares of the company’s stock, valued at $6,204,343.08. This trade represents a 12.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CDNA has been the topic of a number of recent research reports. BTIG Research boosted their price target on shares of CareDx from $60.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, September 24th. William Blair upgraded shares of CareDx to a “hold” rating in a report on Thursday, July 16th. Zacks Research downgraded shares of CareDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. HC Wainwright reissued a “neutral” rating and issued a $46.00 target price on shares of CareDx in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded CareDx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, CareDx presently has an average rating of “Hold” and a consensus price target of $57.00.

About CareDx

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.